Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Monoclonal Antibodies that Neutralize Norovirus
Case ID:
TAB-2636
Web Published:
12/6/2022
Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.
This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Monoclonal_Antibodies_that_N eutralize_Norovirus
Keywords:
antibodies
chimeric
Chimpanzee/Human
DB4BXX
DB4XXX
DBXXXX
DC5XXX
DCXXXX
DXXXXX
Listed LPM Fenn as of 4/15/2015
monoclonal
Neutralize
NORWALK
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
That
virus
VLXXXX
WJXXXX
WNXXXX
XAXXXX
XKXXXX
YCXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Peter Soukas
Technology Licensing Specialist/TTPS
NIH Technology Transfer
301-496-2644
peter.soukas@nih.gov